The SCF ubiquitin E3 ligase regulates ubiquitin-dependent proteolysis of many regulatory proteins such as p27(Kip1), IkappaB, and beta-catenin. We report the isolation of a CUL1 binding protein, p120(CAND1). We found the majority of CUL1 is in a complex with CAND1 and ROC1 independent of SKP1 and F box protein SKP2. Both in vivo and in vitro, CAND1 prevents the binding of SKP1 and SKP2 to CUL1 while dissociation of CAND1 from CUL1 promotes the reverse reaction. Neddylation of CUL1 or the presence of SKP1 and ATP causes CAND1 dissociation. Our data suggest that CAND1 regulates the formation of the SCF complex, and its dissociation from CUL1 is coupled with the incorporation of F box proteins into the SCF complex, causing their destabilization.
The COP9 signalosome (CSN) is a conserved protein complex with homologies to the lid subcomplex of the 26S proteasome. It promotes cleavage of the Nedd8 conjugate (deneddylation) from the cullin component of SCF ubiquitin ligases. We provide evidence that cullin neddylation and deneddylation is highly dynamic, that its equilibrium can be effectively modulated by CSN, and that neddylation allows Cul1 to form larger protein complexes. CSN2 integrates into the CSN complex via its C-terminal region and its N-terminal half region is necessary for direct interaction with Cul1. The polyclonal antibodies against CSN2 but not other CSN subunits cause accumulation of neddylated Cul1/Cul2 in HeLa cell extract, indicating that CSN2 is essential in cullin deneddylation. Further, CSN inhibits ubiquitination and degradation of the cyclin-dependent kinase inhibitor p27(kip1) in vitro. Microinjection of the CSN complex impeded the G1 cells from entering the S phase. Moreover, anti-CSN2 antibodies negate the CSN-dependent p27 stabilization and the G1/S blockage, suggesting that these functions require the deneddylation activity. We conclude that CSN inhibits SCF ubiquitin ligase activity in targeting p27 proteolysis and negatively regulates cell cycle at the G1 phase by promoting deneddylation of Cul1.
Highlights d Liver cholesterol and TAZ are elevated in human and mouse fibrotic NASH d Increased hepatocyte cholesterol upregulates TAZ in human and mouse hepatocytes d Cholesterol blocks TAZ proteasomal degradation via an adenylyl cyclase-RhoA pathway d Silencing the pathway in hepatocytes lowers TAZ and fibrosis in experimental NASH
Hypertrophic differentiation is not only the terminal process of endochondral ossification in the growth plate but is also an important pathological change in osteoarthritic cartilage. Collagen type II (COL2A1) was previously considered to be only a structural component of the cartilage matrix, but recently, it has been revealed to be an extracellular signaling molecule that can significantly suppress chondrocyte hypertrophy. However, the mechanisms by which COL2A1 regulates hypertrophic differentiation remain unclear. In our study, a Col2a1 p.Gly1170Ser mutant mouse model was constructed, and Col2a1 loss was demonstrated in homozygotes. Loss of Col2a1 was found to accelerate chondrocyte hypertrophy through the bone morphogenetic protein (BMP)-SMAD1 pathway. Upon interacting with COL2A1, integrin β1 (ITGB1), the major receptor for COL2A1, competed with BMP receptors for binding to SMAD1 and then inhibited SMAD1 activation and nuclear import. COL2A1 could also activate ITGB1-induced ERK1/2 phosphorylation and, through ERK1/2-SMAD1 interaction, it further repressed SMAD1 activation, thus inhibiting BMP-SMAD1-mediated chondrocyte hypertrophy. Moreover, COL2A1 expression was downregulated, while chondrocyte hypertrophic markers and BMP-SMAD1 signaling activity were upregulated in degenerative human articular cartilage. Our study reveals novel mechanisms for the inhibition of chondrocyte hypertrophy by COL2A1 and suggests that the degradation and decrease in COL2A1 might initiate and promote osteoarthritis progression.
The antioxidative activities of water extract (WE) and crude hot-water soluble polysaccharide (PS) from Ficus carica L. fruit were investigated using various assays in vitro, including scavenging abilities on DPPH, superoxide and hydroxyl radicals and reducing power. The immunity activities of PS were evaluated using the carbon clearance test and serum hemolysin analysis in mice. In addition, total phenolics and flavonoids contents were also determined. Both WE and PS have notable scavenging activities on DPPH with the EC(50) values of 0.72 and 0.61 mg/ml, respectively. The PS showed higher scavenging activity than WE on superoxide radical (EC(50), 0.95 mg/ml) and hydroxyl anion radical (scavenging rate 43.4% at concentration of 4 mg/ml). The PS (500 mg/kg) also has a significant increase in the clearance rate of carbon particles and serum hemolysin level of normal mice. The results indicate that both WE and PS might be applicable in healthy medicine and food industry.
Hepatopoietin (HPO) is a novel polypeptide mitogen specific for hepatocytes and hepatoma cell lines, which is derived from liver and supports its regeneration. To determine whether HPO acts via a receptor-based signal transduction, recombinant human hepatopoietin was labeled by iodination and used to characterize its binding activity by specific displacement test and Scatchard analysis in primarily cultured rat hepatocytes and human hepatoma Hep-G2 cells. The binding was saturable and specific because it was replaceable by HPO but not by epidermal growth factor, transforming growth factor-␣, or insulin. Scatchard analysis indicated the presence of a single class of high affinity receptor with dissociation constant (K d ) of 2 and 0.7 pM, and a receptor density of about 10,000 sites/cell and 55,000 sites/cell in the rat hepatocytes and human hepatoma cells, respectively. The K d values were consistent with the half-maximum dose of HPO activity. Affinity cross-linking of the receptor with 125 I-HPO revealed a polypeptide of molecular mass approximately 90 kDa by SDS-polyacrylamide gel electrophoresis. Thus, the molecular mass of the HPO receptor was calculated to be about 75 kDa. These data demonstrated the existence of an HPO receptor in hepatocytes and hepatoma cells, which may account for biological effect.Previous studies implicate that a small molecule derived from liver itself specifically stimulates hepatocytes proliferation and supports liver regeneration (1-3). In 1975, LaBrecque et al. (3) first reported that in the liver of a weaning rat and the regenerating liver of a partially hepatectomized rat, there existed hepatic stimulator substance (HSS) 1 that could specifically stimulate DNA synthesis in hepatic cells. Other groups have also carried out extensive research on HSS derived from other species (2). At the same time, experiments and clinical research on human fetal liver cells demonstrated its therapeutic effect on hematopoietic diseases and severe liver diseases (2, 4). Since the 1980s, we began to isolate and purify the effective component from fetal liver. We identified hepatic stimulatory activity in the fraction with molecular size ranging from 10 to 30 kDa of human fetal liver lysate (5-7). The activity was target-specific, which was different from various well known nonspecific hepatic stimulators such as insulin, EGF, insulinlike growth factor, and TGF-␣. The characteristics of the effective component derived from human fetal liver were consistent with those of HSSs derived from other species, suggesting that the effective component could be the human-derived homologue of the animal's HSS. Then, we purified this activity and demonstrated that the biological activity of its pure form is identical to those of the crude form and consistent with those of animal-derived HSSs, but evidently different from those of serum-derived hepatocyte growth factor (8). The factor was named as hepatopoietin (HPO). Later, we proved that HPO is encoded by mRNA of fetal liver (9) and further cloned (10) its ...
Hepatopoietin (HPO) is a novel human hepatotrophic growth factor, which specifically stimulates proliferation of cultured primary hepatocytes in vitro and liver regeneration after liver partial hepatectomy in vivo. Recently, the identification of the mitogenic effect of HPO on hepatoma cell lines and the existence of HPO-specific receptors indicate that HPO acts via its specific cell surface receptor. However, the molecular mechanism of HPO action is not fully elucidated. In this report, we examined the signal transduction events induced by HPO in hepatoma cell line (HepG2). Our results demonstrated that HPO induces phosphorylation of mitogenactivated protein kinase kinase and mitogen-activated protein kinase (MAPK) in a rapid and transient manner. HPO stimulates tyrosine phosphorylation of epidermal growth factor receptor (EGFR). Furthermore, we observed that both MAPK activation and the mitogenic effect of HPO on HepG2 cells were completely blocked by AG1478, a specific inhibitor of EGFR tyrosine kinase activity. However, the effects of HPO were not antagonized by an EGFR-blocking antibody, mAb528, which blocks the interaction between epidermal growth factor and EGFR, indicating that stimulation of tyrosine phosphorylation of EGFR by HPO was not mediated by epidermal growth factor. In contrast, genistein, a general tyrosine kinase inhibitor, significantly attenuated the tyrosine phosphorylation of EGFR in response to HPO. In conclusion, our results suggest that tyrosine phosphorylation of EGFR may play a critical role in MAPK activation and mitogenic stimulation by HPO. Hepatopoietin (HPO)1 is a novel human hepatotrophic growth factor, an orthologue of rat augmenter of liver regeneration or hepatic stimulator substance (1). In 1975, LaBrecque and Pesh (2) first reported that in the livers of weanling rats or partially hepatectomized rats, there existed a polypeptide, named hepatic stimulator substance, that could specifically stimulate DNA synthesis of hepatic cells. The existence of hepatic stimulator substance-related activities has been reported in other species including mice, cows, dogs, pigs, and humans (3). Hagiya et al. (4) cloned the cDNA of rat augmenter of liver regeneration, which is the same as rat hepatic stimulator substance. Subsequently, Giorda et al. (5) and Yang et al. (6) cloned the cDNA of human augmenter of liver regeneration or HPO by screening the cDNA library of human fetal liver. HPO encodes a novel protein with no sequence similarity to any known growth regulator. Interestingly, HPO is highly related to the yeast ERV (essential for respiration and viability) gene products. However, the functional relevance of HPO and ERV is currently unclear (7). Yang et al. (8,9) demonstrated that the recombinant human HPO stimulated proliferation of hepatocytes as well as hepatoma cells in vitro. HPO also promotes regeneration and recovery of damaged hepatocytes and rescues acute hepatic failure in vivo (8, 9). Thus, these observations support the contention that HPO is a hepatotrophic growth fa...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.